Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lantheus (LNTH)

Lantheus agrees to sell CDMO business and Springfield, N.J. plant to PharmaLogic

Neutral Impact 4 of 5 m&a

Lantheus entered a definitive agreement on November 8, 2026 to sell its contract development and manufacturing organization business and its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp. The sale is subject to customary closing conditions, and PharmaLogic will also supply lutetium Lu 177 dotatate to Lantheus under a long-term supply agreement, which matters to shareholders as a sale of a business unit with an ongoing supply relationship.

Key points

  • Agreement signed November 8, 2026 to sell the CDMO business and Springfield, New Jersey facility to PharmaLogic
  • Lantheus will provide transition services to PharmaLogic immediately following closing
  • PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus under a long-term supply agreement
  • The filing does not state a purchase price or expected closing date

The filing

CompanyLantheus (LNTH)
Form8-K, current report
Filed with the SECNov 9, 2026, 5:40 PM ET
Accession number0001193125-26-453913

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 6:01 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.